AbbvVie’s (NYSE: ABBV) Humira (adalimumab) - for the treatment of rheumatoid arthritis - will remain the pharmaceutical industry’s biggest selling drug in 2016 with $15.7 billion in forecasted revenues, according to a new report.
The Pharma and Biotech 2016 Preview report, from EP Vantage, the editorial arn of market intelligence and analysis company Evaluate group, predicts Humira will outsell its nearest rival, Gilead’s Hepatitis C drug Harvoni, by more than $4 billion.
The report, published on Fridaty, also forecasts that research and development (R&D) productivity will continue to grow next year and up to 12 new drugs will achieve blockbuster sales by 2020.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze